TD Cowen Upgrades Atara Biotherapeutics (NASDAQ:ATRA) to “Strong-Buy”

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by equities researchers at TD Cowen to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

Several other equities analysts also recently commented on ATRA. Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price objective for the company from $25.00 to $18.00 in a report on Friday, August 16th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.67.

Atara Biotherapeutics Price Performance

Shares of NASDAQ:ATRA opened at $12.18 on Friday. Atara Biotherapeutics has a 12-month low of $6.50 and a 12-month high of $39.50. The business has a 50 day moving average of $9.54 and a 200-day moving average of $10.03. The stock has a market cap of $70.13 million, a PE ratio of -0.47 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same quarter last year, the firm earned ($16.50) earnings per share. Equities research analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATRA. Price T Rowe Associates Inc. MD raised its position in shares of Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics in the second quarter valued at approximately $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics during the second quarter valued at approximately $53,000. FMR LLC lifted its stake in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Vestal Point Capital LP boosted its holdings in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.